Evogene Ltd. (EVGN) is a small, Rehovot, Israel-based computational chemistry company that uses its ChemPass AI platform to design novel small molecules for drug development and crop protection, operating through subsidiaries including AgPlenus and Casterra. In Thursday's session the stock fell 13.34% to $0.3033, down from the previous close of $0.35, a decline of $0.0467 per share. The direction is decisively lower, and the trigger was identifiable: investors reacted to a third-quarter report in which revenue collapsed to near zero on a sequential and annual basis after the Bayer collaboration ended in May 2026, overshadowing a headline loss-per-share beat that was driven by a much larger share count.
Evogene reported third-quarter revenue of approximately $141,000, against roughly $312,000 a year earlier and a consensus estimate near $365,000 to $400,000. The 54.8% year-over-year decline follows the conclusion of the license and collaboration agreement with Bayer, and nine-month revenue fell to about $822,000 from $3.19 million.
The loss per share of $0.17 beat expectations of about $0.19, but the improvement was arithmetic rather than operational. The weighted average share count rose to roughly 16.9 million from 8.7 million, and shares outstanding reached 18.05 million at quarter-end. Loss from continuing operations widened to about $2.81 million from $2.36 million, while the company swung to a net loss of roughly $2.85 million from prior-year net income that had been inflated by asset sales. For a company valued at only about $6 million, a revenue base that has essentially disappeared is a material negative, and the market priced it accordingly.
Cash, cash equivalents, and short-term deposits totaled about $9.2 million at September 30, unchanged from the prior quarter only because roughly $2.4 million was raised through share issuance. Quarterly cash use was about $2.4 million, including a $0.5 million directors-and-officers insurance payment, a pace that funds roughly a year of operations. Shareholders' equity attributable to Evogene turned negative at quarter-end, and no full-year cash-usage guidance was reiterated. That combination keeps financing risk — and the prospect of further dilution — at the center of the investment case.
Management highlighted two internal programs: small-molecule candidates for acute graft-versus-host disease, with IND-enabling work targeted around mid-2027, and AgPlenus fungicide compounds targeting Septoria with up to 75% disease-severity reduction in plant-tissue assays and field work planned for 2027. Both are credible but years from revenue. Critically, no new collaboration agreements were announced in the quarter after four were signed in the first half, removing the catalyst that had supported the stock earlier in the year.
The board appointed Dr. Adi Zuluf-Shani as chairperson effective November 18, following the resignation of the prior chairman disclosed days earlier and the settlement with dissident shareholders approved at the November 10 general meeting. The reshuffle adds uncertainty at the top. Separately, the stock has traded below $1.00 since March 2026, and Nasdaq's extended compliance window runs only to March 29, 2027, with a potential reverse split flagged as a remedy.
The move was company-specific. U.S. indices opened higher Thursday, with the Nasdaq up nearly 2% in early trade after a record AI initial public offering priced above its range, while hawkish Federal Reserve minutes kept pressure on unprofitable micro-caps more broadly. Turnover was light, with roughly 23,000 shares changing hands by midday against a 60-day average near 149,000, a sign the move came from a thin order book rather than heavy institutional distribution. Technically, the stock slipped below its 20-day average near $0.356 and sits about 21% above its 52-week low of $0.2503.
The score runs from 0 — no meaningful news and a routine move — to 100, meaning transformative news and an extreme, rare price swing. Evogene's update lands at 48 out of 100. The fundamental component is solid but not transformative: a steep revenue miss, a widening operating loss, negative equity, and roughly a year of cash runway are highly material for a $6 million company, yet they confirm an existing narrative rather than break new ground. The move was roughly three times the stock's typical 4.5% daily swing, but a decline of this size has occurred twice in the last 60 sessions, including a 29% jump on November 10. Moderate news plus a moderately unusual move produces a mid-range score.
Attention shifts to the fourth-quarter and full-year report, expected in the first quarter of 2027, and to any update on cash-usage guidance that management declined to reaffirm. The most plausible near-term catalyst is a partnership around the Septoria fungicide program, where early partner interest was cited. Investors will also watch for share issuance or other financing, the March 29, 2027 bid-price deadline, and preclinical progress in the aGVHD program. Risks are concentrated: continued revenue near zero, dependence on capital markets, and the possibility of a reverse split. Nothing is assured in either direction.
Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, and only the strongest performers under current market conditions are surfaced in its curated Trending AI Robots section. Bots differ by strategy, timeframe, performance metrics, and the symbols they trade, so the roster shifts as market conditions evolve. For readers who want to see which automated strategies are working right now, reviewing the Trending AI Robots page is a practical next step.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
The Moving Average Convergence Divergence (MACD) for EVGN turned positive on November 11, 2026. Looking at past instances where EVGN's MACD turned positive, the stock continued to rise in 42 of 48 cases over the following month. The odds of a continued upward trend are 88%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where EVGN's RSI Indicator exited the oversold zone, 36 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
Following a +8.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where EVGN advanced for three days, in 142 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
EVGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 35 cases where EVGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EVGN as a result. In 82 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for EVGN entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.302) is normal, around the industry mean (3.592). P/E Ratio (-0.366) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (3.012) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. EVGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of plant traits for the agriculture and biofuel industries
Industry Biotechnology